ONCOTAB, INC.
Total received in grants · trailing 12 months
$1.1M
$0for every U.S. household÷ 131M U.S. households
In perspective
0.0%of all $162.9B in tracked grants
1separate grants, trailing 12 months
ONCOTAB, INC. has received $1.1M across 1 federal grant of $1M or more on record.
Data as of July 24, 2026. Source: USAspending.gov, prime contract awards $1M+. Federal spending data lags and has known gaps. This is not a real-time or complete record.
Grants by agency
Where this recipient’s grant dollars come from.
All grant awards
Swipe to see description and amount →
| Agency | Description | Amount |
|---|---|---|
| Department of Health and Human Services | COMBINATION THERAPY OF T-CELL ENGAGER AND CHEMOTHERAPY FOR PANCREATIC CANCER TREATMENT - THE AMERICAN CANCER SOCIETY ESTIMATES THAT IN 2025 APPROXIMATELY 67,440 NEW CASES OF PANCREATIC CANCER WILL BE DIAGNOSED IN THE UNITED STATES, WITH 51,980 DEATHS. NEARLY 80% OF PATIENTS PRESENT WITH LOCALLY UNRESECTABLE OR METASTATIC DISEASE, WHERE THE 5-YEAR SURVIVAL RATE IS AS LOW AS 3%. STANDARD FIRST-LINE REGIMENS—FOLFIRINOX (5- FU, LEUCOVORIN, IRINOTECAN, OXALIPLATIN) AND GEMCITABINE PLUS NAB-PACLITAXEL (ABRAXANE)—ACHIEVE MEDIAN OVERALL SURVIVAL (MOS) OF UP TO 21 MONTHS, YET OUTCOMES REMAIN DISMAL, UNDERSCORING THE URGENT NEED FOR NOVEL THERAPEUTIC STRATEGIES. ADVANCES IN ANTIBODY ENGINEERING HAVE ENABLED BISPECIFIC ANTIBODIES (BSABS) THAT ENGAGE T CELLS AND REDIRECT THEM TOWARD TUMORS. IN OUR PRIOR PHASE I AWARDS, WE DEVELOPED A PANEL OF BSAB T-CELL ENGAGERS AND IDENTIFIED MUCD3 AS THE LEAD CANDIDATE. PRECLINICAL STUDIES DEMONSTRATED THAT MUCD3 SLOWED TUMOR GROWTH AS MONOTHERAPY AND, WHEN COMBINED WITH ABRAXANE AND GEMCITABINE, SIGNIFICANTLY INHIBITED CHEMOTHERAPY-RESISTANT PANCREATIC TUMORS. IMPORTANTLY, THE COMBINATION ALSO REDUCED CYTOKINE RELEASE, A COMMON LIMITATION OF T-CELL ENGAGERS. IN THIS PHASE II SBIR PROPOSAL, WE WILL ADVANCE MUCD3 THROUGH KEY PRECLINICAL STUDIES DESIGNED TO DE-RISK ITS PATH TOWARD FIRST-IN-HUMAN (FIH) TRIALS AND EVENTUAL COMMERCIALIZATION. MUCD3, PRODUCED FROM LONZA-GENERATED STABLE CELL POOLS, WILL FIRST BE EVALUATED FOR STRUCTURAL STABILITY IN MOUSE SERUM AT 37 °C, FOLLOWED BY PHARMACOKINETIC STUDIES IN HUCD34-NSG AND FCRN MICE TO GUIDE DOSING STRATEGIES. EFFICACY WILL BE ASSESSED IN FOUR TMUC1- POSITIVE PATIENT-DERIVED XENOGRAFT (PDX) ORTHOTOPIC MODELS SPANNING A RANGE OF EXPRESSION LEVELS. IN PARALLEL, CYTOKINE RELEASE ASSAYS IN HUMAN SAMPLES AND A MAXIMUM TOLERATED DOSE (MTD) STUDY IN NON-HUMAN PRIMATES WILL ESTABLISH THE SAFETY MARGIN OF MUCD3 IN COMBINATION WITH NAB-PTX AND GEMCITABINE. THESE ANIMAL MODELS ARE ESSENTIAL TO EVALUATE THE IN VIVO PHARMACOKINETICS, TUMOR-TARGETING EFFICACY, AND SAFETY OF MUCD3 WITHIN AN INTACT BIOLOGICAL SYSTEM, WHICH CANNOT BE FULLY REPLICATED USING IN VITRO APPROACHES. WE WILL COLLABORATE WITH DR. TIM PARDEE (ATRIUM HEALTH WAKE FOREST BAPTIST), DR. MICHAEL MORSE (DUKE HEALTH), AND DR. MOHAMED SALEM (LEVINE CANCER INSTITUTE, ATRIUM HEALTH), WHOSE EXPERTISE IN CLINICAL ONCOLOGY AND TRIAL DESIGN WILL GUIDE EXECUTION OF THESE STUDIES AND THE DESIGN OF THE FIH TRIAL. WE ANTICIPATE THAT MUCD3, COMBINED WITH ABRAXANE AND GEMCITABINE, WILL DEMONSTRATE ENHANCED EFFICACY WITH REDUCED TOXICITY COMPARED TO CURRENT CHEMOTHERAPY, OFFERING THE POTENTIAL TO MEANINGFULLY IMPROVE SURVIVAL AND QUALITY OF LIFE FOR PANCREATIC CANCER PATIENTS | $1,130,587 |